Araştırma Makalesi

Orientinin fare modellerinde anksiyolitik benzeri etkileri: davranışsal ve nörokimyasal incelemeler

Cilt: 50 Sayı: 3 30 Eylül 2025
PDF İndir
EN TR

Anxiolytic-like effects of orientin in mice: behavioral and neurochemical investigations

Abstract

Purpose: Orientin, a water-soluble flavonoid C-glycoside found in various medicinal plants, exhibits diverse pharmacological properties. This study aimed to evaluate its anxiolytic-like effects in mice and to explore the potential roles of adrenergic, serotonergic, and GABAergic neurotransmitter systems in mediating these effects. Materials and Methods: Orientin was administered intraperitoneally to mice at 20, 40, or 80 mg/kg. Anxiolytic-like effects were assessed using the light–dark box, elevated plus maze, hole-board, and open-field tests. For mechanism studies, separate groups received α₂-adrenergic antagonist yohimbine (5 mg/kg), 5-HT1A antagonist WAY-100635 (1 mg/kg), or GABAA antagonist flumazenil (3 mg/kg) prior to 20 mg/kg orientin. Results: Orientin at 20 mg/kg elicited significant anxiolytic-like effects in the hole-board, light–dark box, and open-field tests. The 40 mg/kg dose produced a significant effect only in the hole-board test, whereas the 80 mg/kg dose failed to elicit significant changes in any behavioral paradigm. The pronounced efficacy observed at 20 mg/kg suggests a bell-shaped dose–response profile. Pretreatment with α₂-adrenergic, 5-HT1A serotonergic, or GABAA receptor antagonists partially or completely attenuated the effects of orientin, with the degree of reversal varying among the behavioral assays. Conclusion: The present findings provide compelling evidence that orientin exerts anxiolytic-like effects, potentially mediated via α₂-adrenergic, 5-HT1A serotonergic, and GABAA receptor pathways.

Keywords

Anxiolytic Effects , Flumazenil , Orientin , WAY-100635 , Yohimbine

Kaynakça

  1. Bandelow S, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015;17:327-35.
  2. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593-602.
  3. Merikangas KR, Low NC. Genetic epidemiology of anxiety disorders. Handb Exp Pharmacol. 2005;169:163-79.
  4. Dhawan K, Kumar S, Sharma A. Comparative anxiolytic activity profile of various preparations of Passiflora incarnata linneaus: a comment on medicinal plants' standardization. J Altern Complement Med. 2002;8:283-91.
  5. Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorder. Dialogues Clin Neurosci. 2017;19:93-107.
  6. Miroddi M, Calapai G, Navarra M, Minciullo PL, Gangemi S. Passiflora incarnata L.: ethnopharmacology, clinical application, safety and evaluation of clinical trials. J Ethnopharmacol. 2013;150:791-804.
  7. Deng J, Zhou Y, Bai M, Li H, Li L. Anxiolytic and sedative activities of Passiflora edulis f. flavicarpa. J Ethnopharmacol. 2010;128:148-53.
  8. Lam KY, Ling AP, Koh RY, Wong YP, Say YH. A review on medicinal properties of orientin. Adv Pharm Sci. 2016;2016:4104595.
  9. Ku SK, Kwak S, Bae JS. Orientin inhibits high glucose-induced vascular inflammation in vitro and in vivo. Inflammation. 2014;37:2164-73.
  10. Liu Y, Lan N, Ren J, Wu Y, Wang ST, Huang XF et al. Orientin improves depression-like behavior and BDNF in chronic stressed mice. Mol Nutr Food Res. 2015;59:1130-42.

Kaynak Göster

MLA
Arslan, Tuğçe Selcen, vd. “Anxiolytic-like effects of orientin in mice: behavioral and neurochemical investigations”. Cukurova Medical Journal, c. 50, sy 3, Eylül 2025, ss. 796-05, doi:10.17826/cumj.1679733.